Sales of Lipitor dropped more than £50 million in England last year, as the blockbuster cholesterol drug fell victim to aggressive cost cutting by Primary Care Trusts (PCTs).
The decline in Lipitor is especially significant because it is the surest sign yet that PCTs have seized control of the primary care prescribing budget, and are now dictating the market to GPs and pharmaceutical companies.
Sales of Lipitor (atorvastatin) from GP prescribing fell £53 million in 2007 compared to the previous year, representing a very substantial 15% decline for the UK's biggest selling drug.
More
No comments:
Post a Comment